Anticonvulsants: Seizure-Specific Pharmacology, Dosing and Safety
On this page
1 Overview
Anticonvulsants (antiepileptic drugs, AEDs) suppress abnormal neuronal firing without abolishing normal transmission. Rational prescribing is seizure-specific: narrow-spectrum sodium-channel drugs control focal seizures but can worsen absences and myoclonus, while broad-spectrum agents cover most seizure types. Matching drug to seizure type, knowing each drug's signature toxicities and interactions, and planning around pregnancy are the three habits that define safe AED prescribing.

2 Learning Objectives
- Summarise the five principal mechanisms of anticonvulsant action.
- Match major drugs to the seizure types they treat — and those they worsen.
- Detail the pharmacology, dosing and adverse effects of phenytoin, carbamazepine, valproate, ethosuximide, lamotrigine and levetiracetam.
- Manage toxicity, interactions and therapeutic drug monitoring for classic AEDs.
- Counsel on pregnancy, contraception and adherence.
3 Principles of Action
A seizure is runaway excitation. Anticonvulsants work by one or more of three broad strategies: (1) limiting repetitive firing at voltage-gated sodium channels; (2) reducing excitatory (glutamatergic) transmission; (3) enhancing inhibitory (GABAergic) transmission. The clinical elegance is frequency dependence: sodium-channel blockers bind preferentially to inactivated channels, so they suppress the rapid trains of firing in a seizure focus while leaving ordinary single action potentials — and therefore normal function — largely untouched.
4 The Five Mechanisms of Action
- Sodium-channel blockade — phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, valproate, topiramate, zonisamide.
- Calcium-channel blockade — ethosuximide blocks T-type channels in thalamic neurons (absence seizures); gabapentin/pregabalin bind presynaptic α2δ; zonisamide, valproate act on N/L-type.
- GABA enhancement — benzodiazepines (allosteric GABAA modulators), phenobarbital (prolongs chloride-channel opening), vigabatrin (irreversibly inhibits GABA transaminase), tiagabine (blocks GABA reuptake), valproate (inhibits GABA transaminase).
- Glutamate/NMDA–AMPA antagonism — felbamate, perampanel, topiramate, lamotrigine (reduces glutamate release).
- Synaptic vesicle protein binding — levetiracetam binds SV2A, reducing neurotransmitter release; unique, non-CYP metabolism.
5 Drug Monographs: Doses, Indications & Safety
Each monograph below follows the same exam-ready structure: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses; always confirm against the current Uganda Clinical Guidelines before prescribing.
Phenytoin (hydantoin)
Scroll the table sideways on a smaller screen.
| Phenytoin — sodium-channel blocker | |
|---|---|
| Mechanism | Blocks voltage-gated sodium channels (frequency-dependent, use-dependent binding to inactivated channels) |
| Indications | Focal seizures, generalised tonic–clonic seizures, status epilepticus (IV/loading) |
| Adult dose | Loading 15–20 mg/kg IV (status, max 50 mg/min) or 1 g oral load; maintenance 300 mg/day (3–5 mg/kg/day) once daily or divided |
| Paediatric dose | Maintenance 4–8 mg/kg/day in 2 divided doses |
| Adverse effects | Nystagmus, diplopia, ataxia, slurred speech, confusion (toxicity); gingival hyperplasia, hirsutism, coarse facies, acne; folate-deficiency megaloblastic anaemia, osteomalacia; SJS/TEN |
| Contraindications | Sinus bradycardia/AV heart block; porphyria; caution in pregnancy (teratogenic) and liver disease |
| Interactions | Potent CYP inducer — reduces OCP, warfarin, many antiretroviral levels; metronidazole, cimetidine, fluconazole, valproate raise phenytoin levels; high protein binding (albumin) |
| Patient advice / monitoring | Take with food; never stop abruptly; good oral hygiene (gum hyperplasia); blood levels needed — non-linear kinetics mean small dose increases cause disproportionate level jumps; reliable contraception |
Carbamazepine (iminostilbene)
Scroll the table sideways on a smaller screen.
| Carbamazepine — sodium-channel blocker | |
|---|---|
| Mechanism | Blocks voltage-gated sodium channels; reduces glutamate release |
| Indications | First-line for focal seizures; generalised tonic–clonic seizures; trigeminal neuralgia; bipolar disorder |
| Adult dose | Start 100–200 mg once–twice daily, increase gradually (autoinduction over 2–4 weeks); usual maintenance 400–1,200 mg/day (max 1,600 mg/day) in 2–3 divided doses |
| Paediatric dose | Start 5 mg/kg/day, usual 10–20 mg/kg/day in 2–3 divided doses |
| Adverse effects | Dizziness, diplopia, ataxia, drowsiness, nausea; hyponatraemia/SIADH; SJS/TEN (screen HLA-B*1502 where available); aplastic anaemia, agranulocytosis; hepatotoxicity; teratogenic |
| Contraindications | AV heart block; history of bone-marrow depression; MAOI co-therapy; HLA-B*1502-positive patients (avoid); porphyria |
| Interactions | Potent CYP3A4 inducer — OCP failure, reduced warfarin and antiretroviral effect; erythromycin, clarithromycin, fluconazole, verapamil, diltiazem raise its levels (toxicity); grapefruit juice raises levels; autoinduces its own metabolism |
| Patient advice / monitoring | Take with food, avoid grapefruit; report rash, fever, sore throat, easy bruising, jaundice immediately; baseline + periodic FBC, LFTs, sodium; warn it does not treat absence seizures |
Sodium valproate (carboxylic acid)
Scroll the table sideways on a smaller screen.
| Sodium valproate — broad-spectrum, multiple mechanisms | |
|---|---|
| Mechanism | Multiple: sodium-channel blockade, GABA-transaminase inhibition, T-type calcium-channel blockade |
| Indications | Broad spectrum — all focal and generalised seizures, absence, myoclonus, juvenile myoclonic epilepsy; bipolar disorder; migraine prophylaxis |
| Adult dose | Start 500 mg/day, usual 1,000–2,000 mg/day (20–30 mg/kg/day); status: IV 20–40 mg/kg |
| Paediatric dose | 20–30 mg/kg/day, up to 60 mg/kg/day; avoid in children <2 years on polytherapy |
| Adverse effects | Hepatotoxicity, teratogenicity (neural tube defects, ~10% major malformation rate), weight gain, tremor, hair thinning, GI upset, hyperammonaemic encephalopathy, pancreatitis, PCOS, thrombocytopenia |
| Contraindications | Significant hepatic impairment/urea-cycle disorders; pregnancy unless no alternative; caution in women of childbearing potential |
| Interactions | Inhibitor — raises lamotrigine levels (rash risk) and displaces phenytoin from albumin; carbapenem antibiotics markedly reduce valproate levels; aspirin increases free fraction |
| Patient advice / monitoring | Never in pregnancy — counsel every woman of childbearing potential; folate 5 mg preconception; report jaundice, abdominal pain, unusual bleeding; take with food; monitor LFTs, FBC, weight |
Ethosuximide (succinimide)
Scroll the table sideways on a smaller screen.
| Ethosuximide — T-type calcium-channel blocker | |
|---|---|
| Mechanism | Blocks T-type voltage-gated calcium channels in thalamic neurons |
| Indications | Absence seizures (drug of choice for pure absence); ineffective for tonic–clonic seizures |
| Adult dose | Start 250 mg twice daily; usual 750–1,500 mg/day in 2 divided doses |
| Paediatric dose | Start 15 mg/kg/day, usual 20–40 mg/kg/day in 2 divided doses |
| Adverse effects | GI upset, drowsiness, dizziness, headache, hiccups; rare blood dyscrasias, SLE-like syndrome, psychosis |
| Contraindications | Hypersensitivity; porphyria (caution); not for mixed seizures with tonic–clonic component |
| Interactions | Valproate raises ethosuximide levels; carbamazepine lowers them |
| Patient advice / monitoring | Understand it works only for absence seizures; report rash, fever, sore throat; periodic FBC if long-term; never stop abruptly |
Lamotrigine (phenyltriazine)
Scroll the table sideways on a smaller screen.
| Lamotrigine — sodium-channel blocker, glutamate release inhibitor | |
|---|---|
| Mechanism | Blocks voltage-gated sodium channels; reduces glutamate release |
| Indications | Focal seizures, generalised seizures, absence (with valproate for mixed), bipolar depression |
| Adult dose | Slow titration is mandatory: 25 mg once daily ×14 days → 50 mg ×14 days → 100–200 mg/day maintenance; if combined with valproate, start 25 mg alternate days (max ~100–200 mg/day); if with carbamazepine/phenytoin, higher doses needed |
| Paediatric dose | >12 years: as adult, slower still; 2–12 years specialist titration from 0.15 mg/kg/day (valproate co-therapy) |
| Adverse effects | SJS/TEN (risk ↑ with valproate, rapid titration, children); headache, dizziness, nausea, insomnia, tremor; generally cognition-friendly |
| Contraindications | Hypersensitivity to lamotrigine; caution with valproate co-therapy and previous rash on AEDs |
| Interactions | Valproate doubles its half-life (rash risk); carbamazepine, phenytoin, phenobarbital, rifampicin induce metabolism (lower levels); combined OCP reduces levels ~50% |
| Patient advice / monitoring | Report any rash immediately — stop and seek care; never restart after rash; keep the titration schedule exactly; alert prescribers to OCP use (levels fall) |
Levetiracetam (pyrrolidine)
Scroll the table sideways on a smaller screen.
| Levetiracetam — synaptic vesicle SV2A ligand | |
|---|---|
| Mechanism | Binds synaptic vesicle protein SV2A; reduces neurotransmitter release; non-CYP metabolism |
| Indications | Broad spectrum — focal seizures (first-line), generalised tonic–clonic, myoclonic seizures, JME, status epilepticus (IV) |
| Adult dose | Start 500 mg twice daily; usual 1,000–3,000 mg/day in 2 divided doses; status: IV 1,000–3,000 mg |
| Paediatric dose | Start 10 mg/kg twice daily, up to 60 mg/kg/day |
| Adverse effects | Somnolence, dizziness, headache; behavioural changes — irritability, aggression, depression, rarely psychosis; rare rash, neutropenia |
| Contraindications | Hypersensitivity; caution with significant psychiatric history; reduce dose in renal impairment |
| Interactions | Essentially none — no CYP450 involvement; probenecid may reduce renal clearance; methotrexate levels may rise |
| Patient advice / monitoring | Watch for mood change — report depression, aggression or suicidal thoughts; safest AED profile in pregnancy; no routine level monitoring needed |
Lorazepam (benzodiazepine) — status & acute seizures
Scroll the table sideways on a smaller screen.
| Lorazepam — GABAA allosteric modulator | |
|---|---|
| Mechanism | Potentiates GABAA-mediated chloride influx (allosteric benzodiazepine site) |
| Indications | First-line for status epilepticus and acute repetitive seizure clusters; myoclonus (short-term) |
| Adult dose | Status: 4 mg IV (0.1 mg/kg) at 2 mg/min, may repeat once after 10 minutes; IM 4 mg if no IV access; buccal/intranasal midazolam 10 mg is the community alternative |
| Paediatric dose | 0.1 mg/kg IV (max 4 mg); buccal midazolam 5 mg (1–9 years) / 10 mg (>10 years) |
| Adverse effects | Sedation, respiratory depression, hypotension, confusion, paradoxical agitation; tolerance and dependence with regular use |
| Contraindications | Severe respiratory insufficiency, sleep apnoea, myasthenia gravis, severe hepatic failure |
| Interactions | Additive sedation with opioids, alcohol, antihistamines, other CNS depressants |
| Patient advice / monitoring | Short-term/ emergency use only; monitor airway and respiration after IV dose; never mix with alcohol |
Phenobarbital (barbiturate)
Scroll the table sideways on a smaller screen.
| Phenobarbital — GABAA chloride-channel prolonger | |
|---|---|
| Mechanism | Prolongs GABAA chloride-channel opening; at high doses directly gates the channel |
| Indications | All seizure types (esp. tonic–clonic, focal, neonatal seizures); status epilepticus; cheap mainstay in resource-limited settings |
| Adult dose | 60–180 mg/day at night; status/neonatal loading 20 mg/kg IV |
| Paediatric dose | 3–6 mg/kg/day; neonates: 20 mg/kg load, then 3–4 mg/kg/day |
| Adverse effects | Sedation, cognitive slowing, behavioural change (hyperactivity in children), nystagmus/ataxia, osteomalacia, dependence; rare SJS |
| Contraindications | Porphyria; severe respiratory disease; severe hepatic impairment; caution with depression/suicidality |
| Interactions | Potent CYP inducer — reduces OCP and warfarin efficacy, lowers many co-prescribed drug levels |
| Patient advice / monitoring | Expect drowsiness at first — no driving until stable; never stop abruptly (rebound seizures); reliable contraception needed; serum levels available (toxicity >40 mg/L) |
6 Seizure-Type Selection
Scroll the table sideways on a smaller screen.
| Seizure type | First-line options | Avoid / caution |
|---|---|---|
| Focal-onset | Carbamazepine, lamotrigine, levetiracetam, valproate | — |
| Generalised tonic–clonic | Valproate, lamotrigine, levetiracetam, phenytoin, carbamazepine | — |
| Absence | Ethosuximide (pure absence), valproate, lamotrigine | Carbamazepine, phenytoin — worsen absences |
| Myoclonic / juvenile myoclonic epilepsy | Valproate, levetiracetam, lamotrigine (caution — can worsen myoclonus) | Carbamazepine, phenytoin — exacerbate |
| Infantile spasms | Hormonal therapy (ACTH/prednisolone), vigabatrin (tuberous sclerosis) | — |
| Status epilepticus | Lorazepam → phenytoin/fosphenytoin or valproate or levetiracetam → anaesthesia | — |
7 Adverse Effects & Toxicity
- Phenytoin toxicity — nystagmus, diplopia, ataxia, slurred speech, confusion; chronic: gingival hyperplasia, hirsutism, neuropathy, osteomalacia. Non-linear kinetics make levels essential after dose changes.
- Rash syndromes — carbamazepine, phenytoin, lamotrigine (and phenobarbital) share an aromatic-AED risk of SJS/TEN; HLA-B*1502 (carbamazepine) and HLA-A*3101 screening where available; slow lamotrigine titration is mandatory.
- Valproate — hepatotoxicity (young children, polytherapy), teratogenicity, hyperammonaemia, pancreatitis; monitor LFTs, ammonia if encephalopathic.
- Haematologic — carbamazepine (aplastic anaemia, agranulocytosis), felbamate (aplastic anaemia/hepatic failure — reserved), phenytoin (megaloblastic anaemia from folate depletion).
- Cognitive/psychiatric — barbiturates and topiramate slow cognition (word-finding); levetiracetam can cause irritability and depression.
8 Interactions & Monitoring
- Enzyme inducers — phenytoin, carbamazepine, phenobarbital induce CYP3A4: reduce oral contraceptive reliability (advise alternative methods), lower warfarin, many antiretrovirals and other AED levels.
- Valproate inhibits — raises lamotrigine (rash risk) and phenytoin levels; competes for protein binding.
- Therapeutic drug monitoring — most valuable for phenytoin, carbamazepine, phenobarbital and valproate (check trough levels; levetiracetam and lamotrigine rarely need routine levels). Monitoring helps non-adherence, toxicity, pregnancy, suspected interactions and breakthrough seizures.
- Adherence — single daily-dose agents where possible; missed doses are the commonest cause of breakthrough seizures; never stop abruptly (rebound seizures/status risk).
9 Pregnancy & Special Populations
- Pregnancy — all AEDs carry some teratogenic risk; valproate is the worst (neural tube defects, cognitive impairment, autistic spectrum) and should be avoided in women of childbearing potential unless alternatives fail. Folate 5 mg daily preconception reduces neural-tube risk. Choose the lowest effective dose of the safest drug (lamotrigine, levetiracetam have the best profiles), plan pregnancy with neurology, and monitor levels in pregnancy (clearance rises; dose increases often needed — then reduce postpartum).
- Breastfeeding — generally allowed with lamotrigine, levetiracetam, valproate (low transfer); avoid sedating barbiturates if possible.
- Children — avoid valproate under 2 years (hepatotoxicity); ethosuximide/valproate for absence; many classic drugs need weight-based dosing.
- Elderly — low starting doses, slow titration; watch hyponatraemia (carbamazepine/oxcarbazepine), falls from ataxia, and interactions with polypharmacy.
- HIV/TB co-therapy — enzyme inducers lower antiretroviral and anti-tuberculous drug levels (and rifampicin lowers AED levels) — a daily reality in Ugandan practice; involve specialists.
10 Viva & Exam Points
- Mechanisms — Na⁺ blockade (phenytoin, carbamazepine, lamotrigine), T-type Ca²⁺ blockade (ethosuximide), GABA enhancement (benzos, barbiturates, vigabatrin), glutamate blockade, SV2A binding (levetiracetam).
- Absence — ethosuximide; myoclonic — valproate; narrow-spectrum drugs worsen both.
- Phenytoin — non-linear kinetics, gingival hyperplasia, CYP inducer, nystagmus-ataxia toxicity.
- Carbamazepine — autoinduction, HLA-B*1502/SJS, hyponatraemia, enzyme inducer.
- Valproate — broad spectrum, hepatotoxic, teratogenic, inhibitor.
- Lamotrigine — slow titration, SJS risk; levetiracetam — behavioural effects, no interactions.
- Status — lorazepam IV first, then levetiracetam/valproate/fosphenytoin.
11 References
- Seizure Medications. StatPearls. NCBI Bookshelf — mechanisms and drug profiles.
- Antiepileptic Drug Monitoring. StatPearls. NCBI Bookshelf — therapeutic drug monitoring principles.
- Valproic Acid. StatPearls. NCBI Bookshelf — mechanism, pharmacokinetics, teratogenicity.
- Phenytoin. StatPearls. NCBI Bookshelf — sodium-channel mechanism and toxicities.
- Carbamazepine. StatPearls. NCBI Bookshelf — mechanism and interactions.
For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.